Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of adrenal function assessment after discontinuation of prolonged corticosteroid therapy
2009-015730-30Phase 3Active
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Sep 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Synacthen Depot and tetracosactide hexaacetate in hypoadrenocorticism, sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Technical characteristics of the new diagnostic test. Started Sep 2009; status: active.
02
Drugs
Synacthen Depottetracosactide hexaacetate
03
Conditions
hypoadrenocorticism
Beyond the preview
Go deeper on 2009-015730-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015730-30.